🇺🇸·2h agoIndustry
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Publisher
M
Merck & Co. (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck & Co. (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- July 15, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/2h ago
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
Hyman, Phelps & McNamara (FDA Law)/7h ago
Senate and House Lawmakers Unveil Competing 340B Reform Proposals
Sumitomo Pharma/8h ago
Development of the Regenerative Medicine Product “AMCHEPRY” Receives the 10th Japan Bioindustry Award
Aspen Pharmacare/8h ago